Does internalization of oncolytic reovirus by human dendritic cell carriers protect the virus from neutralization?
The delivery of reovirus via DC could be a promising new approach offering the possibility of combining systemic viral therapy for metastatic disease with induction of an antitumor immune response.
Counseling and early contact improve EBF practice. We believe these two practices would favor better adherence to EBF in other populations.